SCHEMBL5653261

SCHEMBL5653261

CCN(CC)CCCNC(=O)c1ccc(-c2nc3ccc(C(F)(F)F)cc3[nH]2)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.55
HDAC6 Q9UBN7 5/20 0.53
HDAC8 Q9BY41 3/20 0.53
HDAC4 P56524 2/20 0.53
HDAC2 Q92769 2/20 0.53
NPBWR1 P48145 3/20 0.53
DGAT1 O75907 4/20 0.52
KCNH2 Q12809 4/20 0.52
F9 P00740 1/20 0.51
HDAC3 O15379 2/20 0.48
HDAC1 Q13547 2/20 0.48
CHEK2 O96017 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
SOAT1 P35610 2/20 0.48
MCHR1 Q99705 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5653267 0.93 HDAC6 (0.53) FLT3HDAC6HDAC8HDAC4HDAC2
SCHEMBL5651747 0.88 FLT3 (0.53) FLT3HDAC6HDAC8HDAC4HDAC2
SCHEMBL5650980 0.88 FLT3 (0.53) FLT3HDAC6HDAC8HDAC4HDAC2
SCHEMBL5653988 0.86 FLT3 (0.51) FLT3HDAC6HDAC8HDAC4HDAC2
SCHEMBL5647974 0.85 HDAC6 (0.50) FLT3HDAC6HDAC8HDAC4HDAC2
SCHEMBL5653244 0.85 FLT3 (0.51) FLT3HDAC6HDAC8HDAC4HDAC2
SCHEMBL5653300 0.85 FLT3 (0.72) FLT3NPBWR1DGAT1KCNH2F9
SCHEMBL5649315 0.84 HDAC6 (0.54) HDAC6HDAC8HDAC4HDAC2CHEK2
SCHEMBL5647982 0.84 HDAC6 (0.50) HDAC6HDAC8HDAC4HDAC2HDAC3
SCHEMBL5648366 0.84 ACKR3 (0.47) FLT3HDAC6HDAC8HDAC4HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 FLT3 1968/4885HDAC6 537/4885HDAC8 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.